In a move that could reshape how doctors approach both weight and heart health, the American College of Cardiology (ACC) ...

Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...

Thus, both physical activity and GLP-1 RA treatment seem to facilitate weight loss maintenance, improve metabolic health and reduce systemic inflammation. However, diet-induced weight loss decreases ...

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF), a global leader in food, beverage, and health and wellness, has released a new report highlighting how the rapidly growing GLP-1 consumer market is ...

aCancer and Medicine, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark bStatistics and Data Analysis, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark ...

aDepartments of Surgery, New York University, New York, NY, USA bDepartment of Medicine, New York University, New York, NY, USA ...

Logistic regression models were utilized to control for potential confounders such as sex, reporter type, number of suspect drugs, and suspected GLP-1 RA agents. Data analysis categorized 5 ...

That makes the rise in calls to poison control centers for GLP-1 exposure unsurprising, but no less concerning, said Anthony Jaworski, clinical program manager of the Poison Control Center at Children ...

The announcement comes on the heels of mounting evidence linking GLP-1 receptor agonists with eye conditions, including age-related macular degeneration. One such study on NAION risk found that ...

They also took into account sex, age, socioeconomic characteristics, and diabetes duration. By November 30, 2023, 93 (0.2%) of the patients exposed to a GLP-1 RA were newly diagnosed with neovascular ...

The first FDA approved GLP-1 RA was exenatide in 2005, a hypoglycemic agent used in the treatment of T2DM. 1 In 2017, Novo Nordisk introduced semaglutide (Ozempic), a long-acting GLP-1 RA used to ...